Portal de Periódicos da CAPES

Other complications and associated conditions

2007; Wiley; Volume: 8; Issue: 3 Linguagem: Inglês

10.1111/j.1399-5448.2007.00249.x

1399-5448

Olga Kordonouri, Ann Maguire, Mikael Knip, Edith Schober, Renata Lorini, Reinhard W. Holl, Kim C. Donaghue,

Pancreatic function and diabetes

Pediatric DiabetesVolume 8, Issue 3 p. 171-176 Other complications and associated conditions Olga Kordonouri, Olga KordonouriSearch for more papers by this authorAnn M Maguire, Ann M MaguireSearch for more papers by this authorMikael Knip, Mikael KnipSearch for more papers by this authorEdith Schober, Edith SchoberSearch for more papers by this authorRenata Lorini, Renata LoriniSearch for more papers by this authorReinhard W Holl, Reinhard W HollSearch for more papers by this authorKim C Donaghue, Corresponding Author Kim C Donaghue Kim C Donaghuee-mail: [email protected]Search for more papers by this author Olga Kordonouri, Olga KordonouriSearch for more papers by this authorAnn M Maguire, Ann M MaguireSearch for more papers by this authorMikael Knip, Mikael KnipSearch for more papers by this authorEdith Schober, Edith SchoberSearch for more papers by this authorRenata Lorini, Renata LoriniSearch for more papers by this authorReinhard W Holl, Reinhard W HollSearch for more papers by this authorKim C Donaghue, Corresponding Author Kim C Donaghue Kim C Donaghuee-mail: [email protected]Search for more papers by this author First published: 05 June 2007 https://doi.org/10.1111/j.1399-5448.2007.00249.xCitations: 35 Acknowledgements: Thomas Kapellen, Arlan Rosenbloom, and Houssam El-Sabban. Editors of the ISPAD Clinical Practice Consensus Guidelines 2006–2007: Kim Donaghue, Ragnar Hanas, Georgeanna Klingensmith, and Peter Swift. Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL References 1 Bognetti E, Riva MC, Bonfanti R, Meschi F, Viscardi M, Chiumello G. Growth changes in children and adolescents with short-term diabetes. Diabetes Care 1998: 21: 1226– 1229. 2 Donaghue KC, Kordonouri O, Chan A, Silink M. Secular trends in growth in diabetes: are we winning? Arch Dis Child 2003: 88: 151– 154. 3 Gunczler P, Lanes R. Poor metabolic control decreases the growth velocity of diabetic children. Diabetes Care 1999: 22: 1012. 4 Holl RW, Grabert M, Heinze E, Sorgo W, Debatin KM. Age at onset and long-term metabolic control affect height in type-1 diabetes mellitus. Eur J Pediatr 1998: 157: 972– 977. 5 Holl RW, Heinze E, Seifert M, Grabert M, Teller WM. Longitudinal analysis of somatic development in paediatric patients with IDDM: genetic influences on height and weight. Diabetologia 1994: 37: 925– 929. 6 DCCT Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med 1993: 329: 977– 986. 7 Holl RW, Grabert M, Sorgo W, Heinze E, Debatin KM. Contributions of age, gender and insulin administration to weight gain in subjects with IDDM. Diabetologia 1998: 41: 542– 547. 8 Thon A, Heinze E, Feilen KD et al. Development of height and weight in children with diabetes mellitus: report on two prospective multicentre studies, one cross-sectional, one longitudinal. Eur J Pediatr 1992: 151: 258– 262. 9 Codner E, Soto N, Lopez P et al. Diagnostic criteria for polycystic ovary syndrome and ovarian morphology in women with type 1 diabetes mellitus. J Clin Endocrinol Metab 2006: 91: 2250– 2256. 10 Atkinson MA, Eisenbarth GS. Type 1 diabetes: new perspectives on disease pathogenesis and treatment. Lancet 2001: 358: 221– 229. 11 Eisenbarth GS, Gottlieb PA. Autoimmune polyendocrine syndromes. N Engl J Med 2004: 350: 2068– 2079. 12 Sougioultzoglou F, Falorni A, Kassi G, Brozzetti A, Karamitsos D, Koliakos GG. Coincidence of high antiislet and antithyroid autoantibody titles in first-degree relatives of patients with type 1 diabetes. Exp Clin Endocrinol Diabetes 2005: 113: 85– 89. 13 Sumnik Z, Kolouskova S, Malcova H et al. High prevalence of coeliac disease in siblings of children with type 1 diabetes. Eur J Pediatr 2005: 164: 9– 12. 14 Hansen D, Bennedbaek FN, Hoier-Madsen M, Hegedus L, Jacobsen BB. A prospective study of thyroid function, morphology and autoimmunity in young patients with type 1 diabetes. Eur J Endocrinol 2003: 148: 245– 251. 15 Glastras SJ, Craig ME, Verge CF, Chan AK, Cusumano JM, Donaghue KC. The role of autoimmunity at diagnosis of type 1 diabetes in the development of thyroid and celiac disease and microvascular complications. Diabetes Care 2005: 28: 2170– 2175. 16 De Block CE, De Leeuw IH, Vertommen JJ et al. Beta-cell, thyroid, gastric, adrenal and coeliac autoimmunity and HLA-DQ types in type 1 diabetes. Clin Exp Immunol 2001: 126: 236– 241. 17 Holl RW, Bohm B, Loos U, Grabert M, Heinze E, Homoki J. Thyroid autoimmunity in children and adolescents with type 1 diabetes mellitus. Effect of age, gender and HLA type. Horm Res 1999: 52: 113– 118. 18 Kontiainen S, Schlenzka A, Koskimies S, Rilva A, Maenpaa J. Autoantibodies and autoimmune diseases in young diabetics. Diabetes Res 1990: 13: 151– 156. 19 Kordonouri O, Klinghammer A, Lang EB, Gruters-Kieslich A, Grabert M, Holl RW. Thyroid autoimmunity in children and adolescents with type 1 diabetes: a multicenter survey. Diabetes Care 2002: 25: 1346– 1350. 20 Kordonouri O, Hartmann R, Deiss D, Wilms M, Gruters-Kieslich A. Natural course of autoimmune thyroiditis in type 1 diabetes: association with gender, age, diabetes duration, and puberty. Arch Dis Child 2005: 90: 411– 414. 21 Umpierrez GE, Latif KA, Murphy MB et al. Thyroid dysfunction in patients with type 1 diabetes: a longitudinal study. Diabetes Care 2003: 26: 1181– 1185. 22 Aktay AN, Lee PC, Kumar V, Parton E, Wyatt DT, Werlin SL. The prevalence and clinical characteristics of celiac disease in juvenile diabetes in Wisconsin. J Pediatr Gastroenterol Nutr 2001: 33: 462– 465. 23 Calero P, Ribes-Koninckx C, Albiach V, Carles C, Ferrer J. IgA antigliadin antibodies as a screening method for nonovert celiac disease in children with insulin-dependent diabetes mellitus. J Pediatr Gastroenterol Nutr 1996: 23: 29– 33. 24 Carlsson AK, Axelsson IE, Borulf SK et al. Prevalence of IgA-antiendomysium and IgA-antigliadin autoantibodies at diagnosis of insulin-dependent diabetes mellitus in Swedish children and adolescents. Pediatrics 1999: 103: 1248– 1252. 25 Crone J, Rami B, Huber WD, Granditsch G, Schober E. Prevalence of celiac disease and follow-up of EMA in children and adolescents with type 1 diabetes mellitus. J Pediatr Gastroenterol Nutr 2003: 37: 67– 71. 26 De Vitis I, Ghirlanda G, Gasbarrini G. Prevalence of coeliac disease in type I diabetes: a multicentre study. Acta Paediatr Suppl 1996: 412: 56– 57. 27 Hansen D, Bennedbaek FN, Hansen LK et al. High prevalence of coeliac disease in Danish children with type I diabetes mellitus. Acta Paediatr 2001: 90: 1238– 1243 (Comment). 28 Not T, Tommasini A, Tonini G et al. Undiagnosed coeliac disease and risk of autoimmune disorders in subjects with type I diabetes mellitus. Diabetologia 2001: 44: 151– 155. 29 Smith CM, Clarke CF, Porteous LE, Elsori H, Cameron DJ. Prevalence of coeliac disease and longitudinal follow-up of antigliadin antibody status in children and adolescents with type 1 diabetes mellitus. Pediatr Diabetes 2000: 1: 199– 203. 30 Westman E, Ambler GR, Royle M, Peat J, Chan A. Children with coeliac disease and insulin dependent diabetes mellitus – growth, diabetes control and dietary intake. J Pediatr Endocrinol Metab 1999: 12: 433– 442. 31 Saukkonen T, Vaisanen S, Akerblom HK, Savilahti E. Childhood diabetes in Finland Study Group: coeliac disease in children and adolescents with type 1 diabetes: a study of growth, glycaemic control, and experiences of families. Acta Paediatr 2002: 91: 297– 302. 32 Mohn A, Cerruto M, Lafusco D et al. Celiac disease in children and adolescents with type I diabetes: importance of hypoglycemia. J Pediatr Gastroenterol Nutr 2001: 32: 37– 40. 33 Tesei N, Sugai E, Vazquez H et al. Antibodies to human recombinant tissue transglutaminase may detect coeliac disease patients undiagnosed by endomysial antibodies. Aliment Pharmacol Ther 2003: 17: 1415– 1423. 34 Lenhardt A, Plebani A, Marchetti F et al. Role of human-tissue transglutaminase IgG and anti-gliadin IgG antibodies in the diagnosis of coeliac disease in patients with selective immunoglobulin A deficiency. Dig Liver Dis 2004: 36: 730– 734. 35 Cataldo F, Marino V, Bottaro G, Greco P, Ventura A. Celiac disease and selective immunoglobulin A deficiency. J Pediatr 1997: 131: 306– 308. 36 Marsh MN, Crowe PT. Morphology of the mucosal lesion in gluten sensitivity. Baillieres Clin Gastroenterol 1995: 9: 273– 293. 37 Amin R, Murphy N, Edge J, Ahmed ML, Acerini CL, Dunger DB. A longitudinal study of the effects of a gluten-free diet on glycemic control and weight gain in subjects with type 1 diabetes and celiac disease. Diabetes Care 2002: 25: 1117– 1122. 38 Acerini CL, Ahmed ML, Ross KM, Sullivan PB, Bird G, Dunger DB. Coeliac disease in children and adolescents with IDDM: clinical characteristics and response to gluten-free diet. Diabet Med 1998: 15: 38– 44. 39 Corazza GR, Di Sario A, Cecchetti L et al. Influence of pattern of clinical presentation and of gluten-free diet on bone mass and metabolism in adult coeliac disease. Bone 1996: 18: 525– 530. 40 Fabiani E, Catassi C, Villari A et al. Dietary compliance in screening-detected coeliac disease adolescents. Acta Paediatr Suppl 1996: 412: 65– 67. 41 Mustalahti K, Collin P, Sievanen H, Salmi J, Maki M. Osteopenia in patients with clinically silent coeliac disease warrants screening. Lancet 1999: 354: 744– 745. 42 Cerutti F, Bruno G, Chiarelli F, Lorini R, Meschi F, Sacchetti C. Younger age at onset and sex predict celiac disease in children and adolescents with type 1 diabetes: an Italian multicenter study. Diabetes Care 2004: 27: 1294– 1298. 43 Handa S, Dogra S. Epidemiology of childhood vitiligo: a study of 625 patients from north India. Pediatr Dermatol 2003: 20: 207– 210. 44 Verrotti A, Chiarelli F, Amerio PL, Morgese G. Skin diseases in children with type 1 diabetes mellitus. J Eur Acad Dermatol Venereol 1995: 4: 41– 43. 45 Falorni A, Laureti S, Nikoshkov A et al. 21-hydroxylase autoantibodies in adult patients with endocrine autoimmune diseases are highly specific for Addison’s disease. Belgian Diabetes Registry. Clin Exp Immunol 1997: 107: 341– 346. 46 Peterson P, Salmi H, Hyoty H et al. Steroid 21-hydroxylase autoantibodies in insulin-dependent diabetes mellitus. Childhood Diabetes in Finland (DiMe) Study Group. Clin Immunol Immunopathol 1997: 82: 37– 42. 47 Aaltonen J, Bjorses P, Sandkuijl L, Perheentupa J, Peltonen L. An autosomal locus causing autoimmune disease: autoimmune polyglandular disease type I assigned to chromosome 21. Nat Genet 1994: 8: 83– 87. 48 Ahonen P, Myllarniemi S, Sipila I, Perheentupa J. Clinical variation of autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED) in a series of 68 patients. N Engl J Med 1990: 322: 1829– 1836. 49 Dittmar M, Kahaly GJ. Polyglandular autoimmune syndromes: immunogenetics and long-term follow-up. J Clin Endocrinol Metab 2003: 88: 2983– 2992. 50 Chatila TA, Blaeser F, Ho N et al. JM2, encoding a fork head-related protein, is mutated in X-linked autoimmunity-allergic disregulation syndrome. J Clin Invest 2000: 106: R75– R81. 51 Ampudia-Blasco FJ, Girbes J, Carmena R. A case of lipoatrophy with insulin glargine: long-acting insulin analogs are not exempt from this complication. Diabetes Care 2005: 28: 2983. 52 Ampudia-Blasco FJ, Hasbum B, Carmena R. A new case of lipoatrophy with lispro insulin in insulin pump therapy: is there any insulin preparation free of complications? Diabetes Care 2003: 26: 953. 53 Griffin ME, Feder A, Tamborlane WV. Lipoatrophy associated with lispro insulin in insulin pump therapy: an old complication, a new cause? Diabetes Care 2001: 24: 174. 54 Hauner H, Stockamp B, Haastert B. Prevalence of lipohypertrophy in insulin-treated diabetic patients and predisposing factors. Exp Clin Endocrinol Diabetes 1996: 104: 106– 110. 55 Kordonouri O, Lauterborn R, Deiss D. Lipohypertrophy in young patients with type 1 diabetes. Diabetes Care 2002: 25: 634. 56 Saez-De-Ibarra L, Gallego F. Factors related to lipohypertrophy in insulin-treated diabetic patients: role of educational intervention. Pract Diabetes Int 1998: 15: 9– 11. 57 Johansson UB, Amsberg S, Hannerz L et al. Impaired absorption of insulin aspart from lipohypertrophic injection sites. Diabetes Care 2005: 28: 2025– 2027. 58 Thow JC, Johnson AB, Marsden S, Taylor R, Home PD. Morphology of palpably abnormal injection sites and effects on absorption of isophane(NPH) insulin. Diabet Med 1990: 7: 795– 799. 59 De Silva BD, Schofield OMV, Walker JD. The prevalence of necrobiosis lipoidica diabeticorum in children with type 1 diabetes. Br J Dermatol 1999: 141: 593– 594. 60 Kelly WF, Nicholas J, Adams J, Mahmood R. Necrobiosis lipoidica diabeticorum: association with background retinopathy, smoking, and proteinuria. A case controlled study. Diabet Med 1993: 10: 725– 728. 61 Verrotti A, Chiarelli F, Amerio P, Morgese G. Necrobiosis lipoidica diabeticorum in children and adolescents: a clue for underlying renal and retinal disease. Pediatr Dermatol 1995: 12: 220– 223. 62 Boyd AS. Tretinoin treatment of necrobiosis lipoidica diabeticorum. Diabetes Care 1999: 22: 1753– 1754. 63 D’Argento V, Curatolli G, Filotico R, Foti C, Vena GA. Cyclosporin A in the treatment of necrobiosis lipoidica diabeticorum. J Dermatolog Treat 1997: 8: 123– 125. 64 Evans AV, Atherton DJ. Recalcitrant ulcers in necrobiosis lipoidica diabeticorum healed by topical granulocyte-macrophage colony-stimulating factor. Br J Dermatol 2002: 147: 1023– 1025. 65 Ling TC, Thomson KF, Goulden V, Goodfield MJ. PUVA therapy in necrobiosis lipoidica diabeticorum. J Am Acad Dermatol 2002: 46: 319– 320. 66 Moreno-Arias GA, Camps-Fresneda A. Necrobiosis lipoidica diabeticorum treated with the pulsed dye laser. J Cosmet Laser Ther 2001: 3: 143– 146. 67 Nguyen K, Washenik K, Shupack J. Necrobiosis lipoidica diabeticorum treated with chloroquine. J Am Acad Dermatol 2002: 46: S34– S36. 68 Stephens E, Robinson JA, Gottlieb P. Becaplermin and necrobiosis lipoidicum diabeticorum: results of a case control pilot study. J Diabetes Complications 2001: 15: 55– 56. 69 Tidman M. Management of necrobiosis lipoidica. Clin Exp Dermatol 2002: 27: 328– 337. 70 Grgic A, Rosenbloom AL, Weber FT, Giordano B, Malone JI, Shuster JJ. Joint contracture – common manifestation of childhood diabetes mellitus. J Pediatr 1976: 88: 584– 588. 71 Rosenbloom AL, Silverstein JH, Lezotte DC, Riley WJ, Maclaren NK. Limited joint mobility in diabetes mellitus of childhood: natural history and relationship to growth impairment. J Pediatr 1982: 101: 874– 878. 72 Rosenbloom AL, Silverstein JH, Lezotte DC, Richardson K, McCallum M. Limited joint mobility in childhood diabetes mellitus indicates increased risk for microvascular disease. N Engl J Med 1981: 305: 191– 194. 73 Hanna W, Friesen D, Bombardier C, Gladman D, Hanna A. Pathologic features of diabetic thick skin. J Am Acad Dermatol 1987: 16: 546– 553. 74 Monnier VM, Vishwanath V, Frank KE, Elmets CA, Dauchot P, Kohn RR. Relation between complications of type I diabetes mellitus and collagen-linked fluorescence. N Engl J Med 1986: 314: 403– 408. 75 Garg SK, Chase HP, Marshall G et al. Limited joint mobility in subjects with insulin dependent diabetes mellitus: relationship with eye and kidney complications. Arch Dis Child 1992: 67: 96– 99. 76 Starkman HS, Gleason RE, Rand LI, Miller DE, Soeldner JS. Limited joint mobility (LJM) of the hand in patients with diabetes mellitus: relation to chronic complications. Ann Rheum Dis 1986: 45: 130– 135. 77 Silverstein JH, Gordon G, Pollock BH, Rosenbloom AL. Long-term glycemic control influences the onset of limited joint mobility in type 1 diabetes. J Pediatr 1998: 132: 944– 947. 78 Infante JR, Rosenbloom AL, Silverstein JH, Garzarella L, Pollock BH. Changes in frequency and severity of limited joint mobility in children with type 1 diabetes mellitus between 1976-78 and 1998. J Pediatr 2001: 138: 33– 37. 79 Lindsay JR, Kennedy L, Atkinson AB et al. Reduced prevalence of limited joint mobility in type 1 diabetes in a U.K. clinic population over a 20-year period. Diabetes Care 2005: 28: 658– 661. 80 Hirshberg B, Muszkat M, Marom T, Shalit M. Natural course of insulin edema. J Endocrinol Invest 2000: 23: 187– 188. 81 Wheatley T, Edwards OM. Insulin oedema and its clinical significance: metabolic studies in three cases. Diabet Med 1985: 2: 400– 404. Citing Literature Volume8, Issue3June 2007Pages 171-176 ReferencesRelatedInformation